#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neuroendocrine cell hyperplasia of infancy Systemic scleroderma Hepatocellular carcinoma Neuroendocrine carcinoma metastatic Hairy cell leukaemia Acute promyelocytic leukaemia Primary biliary cholangitis Autoinflammation with infantile enterocolitis B-cell small lymphocytic lymphoma refractory Diabetes insipidus Oesophageal carcinoma Neutropenia Alexander disease Systemic candida Anal squamous cell carcinoma More trials…

    Learn about Rare Diseases

    Leiomyosarcoma metastatic – Diagnostics Osteosarcoma recurrent Congenital generalised lipodystrophy – Life with Disease Sjogren’s syndrome – Trials in Disease Cystic fibrosis Biotinidase deficiency Ewing’s sarcoma Isodicentric chromosome 15 syndrome – Trials in Disease Antisynthetase syndrome – Trials in Disease Pemphigus More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    LUNSEKIMIG Bi 1291583 Fluticasone Niflumic Acid Sepiapterin Taurine Ivosidenib Indometacin Skb264 Lecanemab HLX43 Dabigatran Etexilate C1 Esterase Inhibitor (Human) Piracetam Ro7269162 Difelikefalin [11C]Az14193391 Obefazimod Ivermectin Melphalan More therapies…

    Learn about Your Condition

    Aortic stenosis Premature rupture of membranes Head and neck cancer stage IV Radius fracture Hernia repair Alveolar rhabdomyosarcoma Plasma cell leukaemia Erythema multiforme Ovarian cancer stage III Synovial sarcoma metastatic Tumour of ampulla of Vater Hepatitis alcoholic Osteomyelitis Hypercholesterolaemia Neutropenia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

    Recruiting

    3 1 1
    Investigated Drugs:
    • Mk-1084
    • Pembrolizumab
    Austria Bulgaria France Germany Greece Italy +4

  • Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Apalutamide
    • Docetaxel
    France Germany Italy Portugal Spain

  • A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Bevacizumab
    • Sacituzumab Tirumotecan
    Austria Belgium Czechia Denmark Finland France +9

  • A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Vinflunine
    • Docetaxel
    • Paclitaxel
    Belgium France Germany Greece Italy The Netherlands +2

  • A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Doxorubicin Hydrochloride
    • Paclitaxel
    Belgium Denmark Finland France Germany Greece +5

  • A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Docetaxel
    • Prednisone
    Belgium France Germany Italy Spain

  • Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • AMO959
    • Relugolix
    • Degarelix
    France Germany Italy Spain

  • Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Elacestrant
    • Abemaciclib
    Belgium France Germany Greece Italy Spain

  • Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Docetaxel
    France Germany Greece Italy Poland Portugal +1

  • Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • H2-Receptor Antagonists
    • Buclizine Hydrochloride
    • Carboplatin
    Austria Belgium Czechia France Germany Greece +7
1 2 3 … 19
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!